A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
An Exploratory, Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Study, for the Assessment of Efficacy, Safety and Tolerability of Ucb 34714 50 mg Oral Capsules in b.i.d. Administration at the Doses of 200 mg/Day and 400 mg/Day, in Subjects (at Least 18 Years Old) Suffering From Post Herpetic Neuralgia (PHN)
Sponsor: UCB Pharma
Listed as NCT00160667, this PHASE2 trial focuses on Neuralgia, Postherpetic and remains completed. Sponsored by UCB Pharma, it has been updated 9 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UCB Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Annecy, France , Bad Wörishofen, Germany , Bath, United Kingdom , Belgarde, Serbia , Belgrade, Serbia , Bochum, Germany , Bratislava, Slovakia , Brussels, Belgium , Cadiz, Spain , Clermont-Ferrand, France and 40 more locations